MOG and neuromyelitis optica: A 14-day follow-up of patients with COVID-19 ON revealed no significant difference in BCVA compared to that in the MOG-ON group; however, there was a notable improvement in the COVID-19 ON group compared to the NMO-ON group and antibody-negative ON group.